Can transrectal prostate ultrasound compete with multiparametric MRI in the detection of clinically significant prostate cancer?
We consider the current and future role of transrectal ultrasound imaging in the diagnosis of prostate cancer, with a particular focus on the pre-biopsy localization and targeting role that multiparametric MRI (mpMRI) has come to occupy for some men in recent years. We draw a distinction between transrectal ultrasound (TRUS) used only as a means of distributing zonal biopsies with its employment as a means for identifying and targeting sonographically abnormal lesions. The role of AI in lesion identification and targeting will be reviewed. Comparisons of cost and availability, frequency of contraindications and diagnostic accuracy between these two imaging modalities will be drawn.
['Grey|Alistair D R|ADR|', 'Connor|Martin J|MJ|', 'Tam|Joseph|J|', 'Loch|Tillmann|T|']
Prostate cancer multiparametric MRI (mpMRI) transrectal ultrasound (TRUS) artificial neural network analysis multiparametric ultrasound